Table 2.
Risk Factors for Venous Thromboembolism in Endometrial Cancer.a
| Characteristic | No. | 2-year (%) | Univariate |
Multivariate |
||
|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |||
| Age | .06 | .69 | ||||
| <60 | 537 | 6.8% | 1 | 1 | ||
| ≥60 | 177 | 11.4% | 1.70 (0.98-2.94) | 1.15 (0.57-2.32) | ||
| Ethnicity | .87 | .48 | ||||
| Non-Hispanic | 234 | 9.0% | 1 | 1 | ||
| Hispanic | 480 | 7.4% | 0.95 (0.55-1.67) | 1.26 (0.67-2.37) | ||
| BMI (kg/m2) | .10 | .41 | ||||
| <30 | 218 | 11.1% | 1 | 1 | ||
| ≥30 | 490 | 6.5% | 0.65 (0.38-1.10) | 1.31 (0.69-2.48) | ||
| Hypertension | .10 | .88 | ||||
| No | 320 | 9.5% | 1 | 1 | ||
| Yes | 394 | 6.6% | 0.65 (0.39-1.09) | 0.95 (0.49-1.84) | ||
| β-Blocker use | .11 | .40 | ||||
| No | 585 | 8.6% | 1 | 1 | ||
| Yes | 129 | 4.6% | 0.51 (0.22-1.19) | 0.64 (0.23-1.80) | ||
| Diabetes mellitus | .002 | .10 | ||||
| No | 484 | 10.1% | 1 | 1 | ||
| Yes | 230 | 3.4% | 0.32 (0.15-0.68) | 0.39 (0.12-1.22) | ||
| Metformin use | .001 | .54 | ||||
| No | 546 | 9.8% | 1 | 1 | ||
| Yes | 168 | 1.9% | 0.22 (0.08-0.61) | 0.65 (0.16-2.60) | ||
| Hypercholesterolemia | .25 | .25 | ||||
| No | 537 | 8.8% | 1 | 1 | ||
| Yes | 176 | 5.2% | 0.68 (0.35-1.31) | 1.59 (0.73-3.49) | ||
| Statin use | .003 | .14 | ||||
| No | 576 | 9.5% | 1 | 1 | ||
| Yes | 138 | 1.6% | 0.21 (0.06-0.66) | 0.38 (0.10-1.40) | ||
| NAFLD | <.001 | .02 | ||||
| No | 533 | 10.4% | 1 | 1 | ||
| Yes | 181 | 1.7% | 0.13 (0.04-0.41) | 0.24 (0.07-0.79) | ||
| CA-125 (IU/L) | <.001 | <.001 | ||||
| <35 | 457 | 2.8% | 1 | 1 | ||
| ≥35 | 177 | 22.3% | 8.51 (4.53-16.0) | 3.81 (1.78-8.17) | ||
| Platelet count (× 109/L) | <.001 | .01 | ||||
| <400 | 590 | 5.5% | 1 | 1 | ||
| ≥400 | 79 | 24.8% | 5.16 (2.94-9.06) | 2.30 (1.22-4.35) | ||
| Histology subtype | <.001 | .20 | ||||
| Endometrioid | 591 | 5.8% | 1 | 1 | ||
| Nonendometrioid | 123 | 17.4% | 3.57 (2.11-6.04) | 0.61 (0.29-1.30) | ||
| Grade | <.001 | .44 | ||||
| 1-2 | 550 | 4.9% | 1 | 1 | ||
| 3 | 164 | 17.8% | 4.30 (2.56-7.25) | 1.35 (0.64-2.85) | ||
| Stage | <.001 | .86 | ||||
| I-II | 554 | 3.6% | 1 | 1 | ||
| III-IV | 160 | 21.6% | 7.10 (4.10-12.3) | 1.08 (0.45-2.63) | ||
| Recurrence | <.001 | <.001 | ||||
| No | 615 | 3.7% | 1 | 1 | ||
| Yes | 99 | 30.9% | 12.1 (7.01-20.8) | 4.57 (1.97-10.6) | ||
Abbreviations: BMI, body mass index; CA, cancer antigen; CI, confidence interval; HR, hazard ratio; NAFLD, nonalcoholic fatty liver disease; VTE, venous thromboembolism; 2-yr cumulative rate (%), 2-year VTE proportion.
a
Multivariate analysis with Cox proportional hazards regression model for P values. Significant P values are emboldened.